5 results
The primary objective is to demonstrate the superiority of ziltivekimab 15 mg s.c. once-monthly in reducing the risk of MACE (as defined by the primary endpoint) compared to placebo, both added to standard of care, in participants with established…
In this study we will look at the blood levels of the study compound ziltivekimab. We will investigate how quickly and to what extent different compositions of ziltivekimab are absorbed, transported, and eliminated from the body. Ziltivekimab is not…
Primary Objectives: 1) Is it feasible to implement plane-wave imaging in a combined DBT-US device to decrease scan time while preserving or improving image quality compared to conventional imaging? 2) How do DBT images compare obtained by DBT with a…
To study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.
I will test the hypothesis that the noradrenergic system amplifies tremulous activity in the cerebello-thalamo-cortical circuit. More specifically, I will test how this modulation takes place (i.e. through which brain regions and connections).